Comments for discussion are due by Dec. 3, with a focus on the inclusion of certain bulk substances in compounding exemptions under Section 503A of the FD&C Act. The committee will review substances ...
The committee will discuss bulk drug substances being considered for inclusion on the 503A Bulk Drug Substances List, including AOD-9604-related, CJC-1295-related, and Thymosin alpha-1-related ...